Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">No of eyes</td><td class="align_center">10</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Men/women</td><td class="align_center">5/5</td></tr><tr><td class="align_left">Age, years</td><td class="align_center">80.9 ± 6</td></tr><tr><td class="align_left">MNV type</td><td class="align_center">9/10</td></tr><tr><td class="align_left"> Type 1</td><td class="align_center">7</td></tr><tr><td class="align_left"> Type 2</td><td class="align_center">1</td></tr><tr><td class="align_left"> Type 3</td><td class="align_center">1</td></tr><tr><td class="align_left">Central retinal thickness, <i>μ</i>m</td><td class="align_center">461.7 ± 82.9</td></tr><tr><td class="align_left">PED, <i>μ</i>m</td><td class="align_center">202.5 ± 82.7</td></tr><tr><td class="align_left">BCVA, logMAR</td><td class="align_center">0.67 ± 0.4</td></tr><tr><td class="align_left">MNV size, mm3</td><td class="align_center">0.85 ± 1.1</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>BCVA = best corrected visual acuity; MNV = macular neovascularization; OCTA = optical coherence tomography angiography, PED = pigment epithelium detachment.<br/></div></td></tr></table>

<div>Baseline characteristics of 10 treatment-naïve neovascular age-related macular degeneration patients.</div>

Journal of Ophthalmology

tab1

Table 1

Table 1: Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting 

Table 1 | Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting 